A LinkedIn post from Touchlight highlights the company’s planned participation at the ASGCT 2026 conference, where it is scheduled to present on novel lipid-based formulations for delivery of cell-free single-stranded DNA (mbDNA™). The talk, co-presented with Sartorius, is described as focusing on enabling improved homology-directed repair (HDR) knock-in in primary human T cells.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Touchlight is positioning its mbDNA™ platform within emerging non-viral delivery workflows for cell and gene therapy applications. For investors, this conference visibility and technical collaboration with Sartorius may indicate efforts to deepen Touchlight’s role in DNA manufacturing and non-viral delivery ecosystems, potentially enhancing its relevance to partners in gene and cell therapy development.
The emphasis on improved HDR in primary T cells points to possible applications in engineered cell therapies, an area of active investment and competition. While the post does not disclose commercial terms or partnerships, it implies ongoing R&D alignment with industry demand for scalable, non-viral approaches, which could support Touchlight’s long-term positioning in advanced therapeutics manufacturing.